28th NOV, 2007
Abstract Submission Deadline Nurses Group.
Abstract Submission Deadline Physicians & Data Management Group.
Deadline for early registration (reduced fee) and Hotel reservation.
Notification for acceptance of abstracts.
Final Programme available on the Internet.
Deadline for intermediate registration fee.
2nd Patient & Family Day, Florence, Italy.
EBMT 2008 congress in progress, Florence, Italy.
Please for more information about a specific meeting refer to:
30th MAR–2nd APR, 2008
EBMT 2008
| Retrospective Analyses |   |
Clinical Trials | |
|
Seventh Framework Programme | |
Educational Course |
The HDR-Allo protocol (Allogeneic Stem Cell Transplantation using a Reduced Intensity Conditioning Protocol for Patients with Relapsed / Refractory Hodgkins’ Lymphoma) was officially closed at the General Meeting of the LWP in Lyon 2006 due to a low accrual of patients. Nevertheless, 62 patients were included in this prospective clinical trial mainly from Spanish centres, so we have decided to proceed with the information we have and the final statistical analysis will be performed during the second half of 2008.
Seventh Framework Programme
We have submitted a collaborative proposal for the second call (deadline 18th September 2007) of the Seventh Framework Programme of the European Comission under the following topic:
“HEALTH-2007-2.4.1-9: Innovative combination clinical trials for multimodal cancer therapy. Collaborative efforts combining novel radiation therapy strategies with either chemotherapy, immunotherapy and/or other biologically-based therapeutic strategies in a phase I or II setting should result in improving quality of life and/or survival of patients suffering from cancer”.
The proposal is the following:
“A phase I/II European multicenter trial evaluating the new radioimmunoconjugate 90Ytrium-Daclizumab (ZenaRX) combined with hig-dose chemotherapy uin patients with relasped or refractory Hodgkin’s Lymphoma” constitutes a cooperative European effort leaded by Prof. Dr. Andreas Engert ftrom University of Cologne – German Hodgkin Study Group at the University of Cologne together with a consortium of all major European study groups active in the treatment of patients with Hodgkin’s Lymphoma (EORTC, Belgium; GEL/TAMO, Spain; GELA, France; UK NCRI, United Kingdom; NIH, U.S; HKR, Denmark; EBMT, Netherlands; AMC, Netherlands). In addition, three industrial partners are in this application. Their part is to produce clinical-grade study material, handle the data management and support the steering committee in the management of this consortium.
90Ytrium-Daclizumab has shown a very selective and specific binding to tissues involved with Hodgkin’s klymphoma and has resulted in impressive response rates when used as single agent in patients with multiply relapsed Hodgkin’s lymphoma. The basic concept underlying this project is that the use of radioimmunotherapy may further improve systemic control of Hodgkin’s Lymphomas as well as improve the radiation therapeutic index.
We propose to use escalated, non-myeloablative doses of 90Ytrium-Daclizumab as part of a conditioning regimen for cytoreduction followed by BEAM and hematopoietic stem cell support. This approach may allow a greater proportion of patients with recurrent and refractory Hodgkin’s lymphoma to achieve superior freedom from progression intervals and also impact overall survival.
90Ytrium-Daclizumab will be used in combination with salvage chemotherapy (2 cycles of DHAP) and will be followed by high-dose chemotherapy (BEAM) and autologous stem cells to evaluate the feasibility of combined radioimmunotherapy and high-dose chemotherapy.
This is a phase I/II clinical trial in which escalating doses of 90Ytrium-Daclizumab will be evaluated in cohorts of 3-6 patients per dose. A fixed dose will be used in the phase II part of the trial. The overall goal of this phase I/II trial is to evaluate efficacy, feasibility and safety of this combined radioimmuno-chemotherapy in patients with relapsed/refractory Hodgkin’s lymphoma, to evaluate the effects of this new treatment in the immune system of the patient treated and to compare the results of this trial with those observed using identical chemotherapy without the additional radioimmunotherapy’.
The Lymphoma Working Party Educational Course
|
Participants at the LWP Educational Course in Prague |
For the last three years the LWP has been organising annual Educational Courses focused on Hematopoietic Stem Cell Transplantation and Lymphomas. These courses are aimed at Young Physicians who have graduated in the last two years with the objective of actively involving them in the activities of the LWP, to share experiences through case reports and to enhance knowledge. In addition, these courses aim to facilitate communication between BMT professionals from different countries across Europe.
After the success and excellent scientific evaluation made by the participants in the first two courses held in Barcelona, Spain, 2005 (local organiser: Anna Sureda) and Prague, Czech Republic, 2006 (local organiser: Marek Trneny), this year’s course will be taking place in Hamburg, Germany under the local organisation of Prof. Norbert Schmitz. This year there will be a general overview covering the principles of autologous transplantation, the principles of allogeneic transplantation and an overview on transplants in lymphoma followed by four Disease Specific sessions delivered by experts on the following topics: Hodgkin's Disease, Aggressive Lymphoma, Indolent Lymphoma and Rare Lymphomas.
At the end of each session there will be the opportunity for delegates to prepare and present two case reports per session which should provide a springboard for further discussions. This year we are pleased to offer eight full scholarships for chosen case reports as well as six Outreach Scholarships. We will be holding the 2008 course in Sofia, Bulgaria in an attempt to encourage more participants from Central and Eastern European countries. Information regarding all LWP Educational Courses can be found on the working party webpages.
I really hope that all this news that I have tried to briefly summarise is of interest to you and that it stimulates your scientific interest highly enough to encourage you and the young investigators of your team to actively participate in the LWP. There are many ideas and projects that can be developed at a European level, we need to continue to strenghen our structure with highly-motivated people with the sole aim of developing prospective projects of a high scientific level.
Anna Sureda
Chair, Lymphoma WP
Page < 1 - 2 >
